Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Taysha Gene Therapies Announces January 2022 Virtual Investor Events To Review Preliminary Clinical Data For TSHA-101 In GM2 Gangliosidosis And High Dose Cohort And Long-Term Clinical Data For TSHA-120 In Giant Axonal Neuropathy

By Bill Haddad
Today, 2:17 AM
Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central

TSHA